Stock KYMR KYMERA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Market Closed - Nasdaq
Other stock markets
 21:00:02 01/05/2024 BST 		5-day change 1st Jan Change
36.2 USD +7.66% Intraday chart for Kymera Therapeutics, Inc. +2.80% +42.16%
04-22 Oppenheimer Starts Kymera Therapeutics With Outperform Rating, $53 Price Target MT
04-08 Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting
Kymera Therapeutics, Inc. Appoints Felix J. Baker to the Board
Kymera Therapeutics Insider Sold Shares Worth $14,912,376, According to a Recent SEC Filing
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs At the American Academy of Dermatology Annual Meeting
Kymera Therapeutics Q4 Net Loss Narrows, Collaboration Revenue Rises
Kymera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Kymera Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Kymera Therapeutics Insider Sold Shares Worth $300,470, According to a Recent SEC Filing
Kymera Therapeutics Raises $316.2 Million From Offering, Outlines Cash Runway Guidance
Kymera Therapeutics Prices $275 Million Common Share Public Offering
Kymera Therapeutics Launches $250 Million Public Share Offering
Kymera Therapeutics, Inc. Intends to Initiate A Phase 1 Clinical Trial in the Second Half of 2024 and Report the Phase 1 Results in 2025
Kymera Therapeutics Shares Decline on BofA Securities Downgrade
Kymera Therapeutics, Inc. Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474p
Kymera Therapeutics, Inc. Announces Publication of Phase 1 Trial Results for KT-474, a First-In-Class IRAK4 Degrader, in Nature Medicine
Kymera Therapeutics, Inc. to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
Kymera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Kymera Therapeutics Reports First Patient Dosing in Mid-Stage Hidradenitis Suppurativa Trial
Kymera Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KYMR Stock
  4. News Kymera Therapeutics, Inc.
  5. Other languages